FutureWorld (OTCMKTS:FWDG) and Epizyme (NASDAQ:EPZM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.
This table compares FutureWorld and Epizyme’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares FutureWorld and Epizyme’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Epizyme||$10.00 million||94.29||-$134.30 million||($2.18)||-5.46|
FutureWorld has higher earnings, but lower revenue than Epizyme.
Institutional & Insider Ownership
73.8% of Epizyme shares are held by institutional investors. 21.5% of Epizyme shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
FutureWorld has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Epizyme has a beta of 3, indicating that its stock price is 200% more volatile than the S&P 500.
This is a breakdown of current recommendations for FutureWorld and Epizyme, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Epizyme has a consensus target price of $19.86, suggesting a potential upside of 66.73%. Given Epizyme’s higher probable upside, analysts clearly believe Epizyme is more favorable than FutureWorld.
Epizyme beats FutureWorld on 6 of the 9 factors compared between the two stocks.
FutureWorld Corp., together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of hemp/cannabis products, services, and technologies worldwide. The company provides smart sensor technology, communication network, surveillance security, data analysis for smart cultivation, and consultation for the industrial hemp and legal medicinal marijuana. It offers personal and professional tetrahydrocannabinoil and Cannabidiol test kits; pharmaceutical grade CBD oil solutions; URVape vaporizer pens, which are oil vaporizers for the e-cigarette, cannabis, and herbal vaping industry; CaNNaLyTiX, a dashboard controller system that allows various computer systems to be integrated throughout a cultivator's infrastructures; CaNNaTRAK, the barcode and RFID tracking systems for keeping seed to sale tracking of hemp/cannabis; and SPIDer (secure perimeter intrusion detection network), a system to meet the needs of theft and malicious attacks. The company also provides SmartSense, which offers wireless security and smart sensor mesh network for precision agriculture, irrigation systems, and greenhouses for the hemp industry; SmartNergy that offers tools to analyze various aspects of a cultivator's energy usage; and CaNNaBoX machine, which operates with the swipe of a card to verify identity, age, and prescription information of a medical marijuana patient before releasing measured packages of marijuana. Its target customers include consumers via Internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, affiliate sales, and master distributors. The company was formerly known as FutureWorld Energy, Inc. and changed its name to FutureWorld Corp. in June 2014. FutureWorld Corp. was founded in 2002 and is based in Saint Petersburg, Florida.
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Eisai Co. Ltd.; Lymphoma Study Association; and Boehringer Ingelheim. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for FutureWorld Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FutureWorld and related companies with MarketBeat.com's FREE daily email newsletter.